TY - JOUR
T1 - Myeloid neoplasms after breast cancer
T2 - "Therapy-related" not an independent poor prognostic factor
AU - Chen, Yiming
AU - Estrov, Zeev
AU - Pierce, Sherry
AU - Qiao, Wei
AU - Borthakur, Gautam
AU - Ravandi, Farhad
AU - Kadia, Tapan
AU - Brandt, Mark
AU - O'brien, Susan
AU - Jabbour, Elias
AU - Garcia-Manero, Guillermo
AU - Cortes, Jorge
AU - Beran, Miloslav
N1 - Publisher Copyright:
© 2014 Informa UK, Ltd.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Abstract Two hundred and thirty-five consecutive patients presenting to a single center with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer treatment were compared with matched patients with de novo AML or MDS. There was no significant difference in median overall survival (OS) times between patients with therapy-related AML and those with de novo AML (8.7 months vs.10.2 months; p = 0.17). Patients with therapy-related MDS had slightly lower median baseline platelet counts and a higher frequency of poor cytogenetics than those with de novo MDS, but the two groups had similar OS times (13.6 months vs. 18.9 months; p = 0.06). Multivariate analysis revealed that cytogenetic risk, baseline white blood cell count, age and performance status were predictive for OS time in AML and that cytogenetic risk and performance status were predictive for OS time in MDS. Having therapy-related disease is not an independent risk factor in patients with myeloid neoplasms and with a history of breast cancer. Clinical trials should be designed to serve both populations.
AB - Abstract Two hundred and thirty-five consecutive patients presenting to a single center with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer treatment were compared with matched patients with de novo AML or MDS. There was no significant difference in median overall survival (OS) times between patients with therapy-related AML and those with de novo AML (8.7 months vs.10.2 months; p = 0.17). Patients with therapy-related MDS had slightly lower median baseline platelet counts and a higher frequency of poor cytogenetics than those with de novo MDS, but the two groups had similar OS times (13.6 months vs. 18.9 months; p = 0.06). Multivariate analysis revealed that cytogenetic risk, baseline white blood cell count, age and performance status were predictive for OS time in AML and that cytogenetic risk and performance status were predictive for OS time in MDS. Having therapy-related disease is not an independent risk factor in patients with myeloid neoplasms and with a history of breast cancer. Clinical trials should be designed to serve both populations.
KW - Chemotherapeutic approaches
KW - Myeloid leukemias and dysplasias
KW - Prognostication
UR - http://www.scopus.com/inward/record.url?scp=84929069799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929069799&partnerID=8YFLogxK
U2 - 10.3109/10428194.2014.946023
DO - 10.3109/10428194.2014.946023
M3 - Article
C2 - 25048874
AN - SCOPUS:84929069799
SN - 1042-8194
VL - 56
SP - 1012
EP - 1019
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -